Table 2.
The Relationship Between Protein Expression and Chemotherapy Efficacy
| Protein | CR + PR | SD + PD | Chi-Square Value | p Value |
|---|---|---|---|---|
| P-gp | 0.834 | 0.361 | ||
| + | 25 (59.5%) | 35 (68.6%) | ||
| − | 17 (40.5%) | 16 (31.4%) | ||
| GST-π | 0.530 | 0.467 | ||
| + | 15 (35.7%) | 22 (43.1%) | ||
| − | 27 (64.3%) | 29 (56.9%) | ||
| Topo II | 0.645 | 0.419 | ||
| + | 32 (76.2%) | 35 (68.6%) | ||
| − | 10 (23.8%) | 16 (31.4%) | ||
| MRP | 0.782 | 0.377 | ||
| + | 12 (28.6%) | 19 (37.3%) | ||
| − | 30 (71.4%) | 32 (62.7%) | ||
| LRP | 1.705 | 0.192 | ||
| + | 26 (61.9%) | 38 (74.5%) | ||
| − | 16 (38.1%) | 13 (25.5%) | ||
| Ki-67 | 8.570 | 0.003 | ||
| + | 33 (78.6%) | 25 (49.0%) | ||
| − | 9 (21.4%) | 26 (51.0%) | ||
| p53 | 6.821 | 0.009 | ||
| + | 11 (26.2%) | 29 (56.9%) | ||
| − | 31 (73.8%) | 22 (43.1%) |
P-gp, P-glycoprotein; GST-π, glutathione S-transferase-π; topo II, topoisomerase II; MPR, multidrug resistance gene-associated protein; LRP, lung resistance-related protein; CR, complete remission; PR, partial remission; SD, stable disease; PD, disease progression.